NuVasive, Inc.
7475 Lusk Blvd.
San Diego
California
92121
United States
476 articles about NuVasive, Inc.
-
NuVasive Announces Conference Call and Webcast of Third Quarter 2022 Results
10/25/2022
NuVasive, Inc. announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close.
-
NuVasive to Sponsor and Participate at EUROSPINE 2022
10/17/2022
NuVasive, Inc. today announced it will continue its partnership with EUROSPINE as a gold sponsor and will attend EUROSPINE 2022 held October 19 to 21 in Milan.
-
NuVasive Announces Agenda for Investor Day 2022
9/29/2022
NuVasive, Inc. has announced the planned agenda for the Company's Investor Day 2022, which will be hosted at the NuVasive West Coast Experience Center in San Diego on Thursday, October 6, 2022, with presentations beginning at 9:00 a.m. PT.
-
NuVasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio
9/28/2022
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Reline® Cervical, a new fixation system for posterior cervical fusion (PCF), in targeted regions.
-
NuVasive to Sponsor and Participate at Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum '22
9/26/2022
NuVasive, Inc. today announced it will continue its partnership with the Society for Minimally Invasive Spine Surgery (SMISS) as a sponsor and will attend the SMISS Annual Forum '22 held September 29 to October 1, 2022 in Las Vegas.
-
NuVasive to Participate in Upcoming Investor Conferences
8/23/2022
NuVasive, Inc. announced today that management will participate in the following investor conferences.
-
NuVasive Announces Departure of Chief Commercial Officer
8/9/2022
NuVasive, Inc. (NASDAQ: NUVA), today announced the resignation of Massimo Calafiore, executive vice president and chief commercial officer, effective August 31, 2022, to become the chief executive officer of a privately-held, orthopedics technology company.
-
NuVasive to Participate in Canaccord Genuity 42nd Annual Growth Conference
7/28/2022
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Financial Officer Matt Harbaugh will participate in the Canaccord Genuity 42nd Annual Growth Conference in Boston on Thursday, August 11, 2022.
-
Clinical Study Validates NuVasive Porous Interbody Implant and Synthetic Bone Graft Substitute as Cost-effective Solution for Lateral Lumbar Interbody Fusions
7/26/2022
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the results of the study "Can a bioactive interbody device reduce the cost burden of achieving lateral lumbar fusion?" in the Journal of Neurosurgery: Spine.
-
NuVasive Announces Conference Call and Webcast of Second Quarter 2022 Results
7/18/2022
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter results on Wednesday, August 3, 2022, after the close of the market.
-
NuVasive Opens Singapore Experience Center for Asia-Pacific region
6/29/2022
NuVasive, Inc. announced the grand opening of its Singapore Experience Center for the Asia-Pacific region, supporting the Company's growth strategy to globalize its business.
-
NuVasive Announces First Quarter 2022 Financial Results
5/4/2022
NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced financial results for the quarter ended March 31, 2022.
-
NuVasive Specialized Orthopedics Surpasses 100 Peer-Reviewed Publications of the Precice System for Limb Lengthening
4/26/2022
NuVasive, Inc. announced a milestone of more than 100 peer-reviewed publications of the Precice® System for conditions related to limb lengthening and reconstruction from NuVasive Specialized Orthopedics™.
-
NuVasive Simplify Cervical Disc Two-level Data Published in Journal of Neurosurgery: Spine
4/21/2022
NuVasive, Inc. today announced the NuVasive Simplify® Cervical Disc (Simplify Disc) two-level U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study data was recently published in the Journal of Neurosurgery: Spine.
-
NuVasive Announces Conference Call and Webcast of First Quarter 2022 Results
4/20/2022
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter results on Wednesday, May 4, 2022, after the close of the market.
-
NuVasive Announces Fourth Quarter and Full Year 2021 Financial Results and 2022 Outlook
2/23/2022
NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2021.
-
NuVasive to Participate in 42nd Annual Cowen Healthcare Conference
2/22/2022
NuVasive, Inc. announced that Chief Executive Officer Chris Barry will virtually present at the 42nd Annual Cowen Healthcare Conference on Tuesday, March 8, 2022 at 8:10 a.m. PT / 11:10 a.m. ET.
-
NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full Year 2021 Results
2/8/2022
NuVasive, Inc. announced the Company will release its fourth quarter and full year 2021 results on Wednesday, February 23, 2022, after the close of the market.
-
NuVasive Appoints Andrew C. Morton as Chief Human Resources Officer
1/31/2022
NuVasive, Inc. today announced the appointment of Andrew (Drew) C. Morton as senior vice president and chief human resources officer (CHRO) effective February 7, 2022 .
-
NuVasive Receives FDA Clearance for Expanded Indications of Use for Attrax Putty with Company's Thoracolumbar Interbody Portfolio
1/5/2022
NuVasive, Inc. (NASDAQ: NUVA), today announced the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications of use for Attrax® Putty with its comprehensive thoracolumbar interbody portfolio for spine surgery.